|Day Low/High||142.64 / 148.08|
|52 Wk Low/High||127.10 / 223.24|
Quest and IBM are rolling out a genomic sequencing service powered by Big Blue's Watson supercomputer.
Do that if you like top ticking crowd favorites, but set a protective stop.
If Twitter puts up a dreadful quarter, shares will sell off again.
We’ll wait until we have more clarity on the issues that plagued the September quarter before considering entry points.
Don't focus on just one day of trading, Jim Cramer says.
Illumina fell 24% on news that it was cutting revenue guidance.
Wall Street sells off as a disappointing quarterly performance from Alcoa heralds a poor start to the third-quarter earnings season and crude oil retreats from highs.
On days like this, the money just keeps sloshing around.
Stock losses accelerate on Tuesday afternoon as a disappointing quarterly performance from Alcoa heralds a poor start to the third-quarter earnings season.
U.S. stocks slipped after a disappointing quarterly performance from Alcoa soured optimism over earnings season.
Cantor Fitzgerald says Illumina's outlook revision is not likely to affect industry peers.
Stocks slip on Tuesday as a disappointing quarterly performance from Alcoa sours optimism over the earnings season.
Illumina (ILMN) cut its third-quarter revenue forecast and was downgraded by Citi and Janney Capital.
Shares of Illumina were tanking before the opening bell after unveiling a disappointing sales forecast.
Here are Tuesday's top research calls, including upgrades for Encana, Norfolk Southern, Seagate and Tyson.
Oil is likely to be in focus once again Tuesday after Monday brought no new economics news and little corporate news.
Illumina (ILMN) reduced its third-quarter revenue forecast late Monday.
Illumina, Inc. (NASDAQ: ILMN) today announced estimated third quarter revenue of approximately $607 million, a 10% increase compared to $550 million in the third quarter of 2015.
The squeeze is on these stocks, and they are poised for volatile moves.
I have been a big bull on its technology, but I am sidelined right now.
Illumina, Inc. (NASDAQ: ILMN) today announced that it will webcast the company's presentation at the Morgan Stanley Global Healthcare Conference in New York, NY, on September 13, 2016.
The most recent short interest data has been released for the 08/15/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
Despite tepid market reaction, and analyst skepticism, there might be some upside for TMO.
The potential transaction could be a true game-changer that makes sense strategically and financially, albeit dilutive near term.
Thermo Fisher Scientific (TMO) has reportedly offered $30 billion to acquire Illumina (ILMN).
Illumina, Inc. (NASDAQ: ILMN) and FlowJo, LLC, today announced a partnership to develop and co-market analysis software for single cell next-generation sequencing (NGS) data.